Pharmaceutical approaches to colon targeted drug delivery systems

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 1, 2003, Pages 33-66

  Chourasia, M K ^a   Jain, S K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; AMYLOSE; AZO REDUCTASE; BALSALAZIDE; BUDESONIDE; CYCLODEXTRIN; CYCLOSPORIN; DEXAMETHASONE DERIVATIVE; DRUG CARRIER; FLUDROCORTISONE; GLYCOSIDASE; GUAR GUM; HYDROCORTISONE; INSULIN; INULIN; IPSALAZIDE; MESALAZINE; METHYLPREDNISOLONE; NALMEFENE; NALOXONE; OLSALAZINE; PECTIN; POLYMER; POLYSACCHARIDE; PREDNISOLONE DERIVATIVE; PRODRUG; SALAZOSULFAPYRIDINE; SENNOSIDE; SULFAPYRIDINE; UNINDEXED DRUG;

AMEBIASIS; ANTIINFLAMMATORY ACTIVITY; ASCENDING COLON; COLON CROHN DISEASE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; COVALENT BOND; CROSS LINKING; DIARRHEA; DRUG ABSORPTION; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STRUCTURE; ENTERITIS; ENZYME ACTIVITY; HUMAN; HYDROPHILICITY; INTESTINE ABSORPTION; INTESTINE FLORA; INTESTINE TRANSIT TIME; NEPHROTOXICITY; NONHUMAN; PERMEABILITY BARRIER; PH; REVIEW; SIDE EFFECT; TARGET ORGAN; ULCERATIVE COLITIS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COLONIC DISEASES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0038725720     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (236)

1. Sarasija, S. and Hota, A., Colon-specific drug delivery systems. Ind J Pharm Sci, 62: 1-8, 2000.
2. Raffi, R., Franklin, W. and Cerniglia, C.E., Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora. Appl Environ Mivrobiol, 56: 2146-2151, 1990.
3. Raffi, R., Franklin, W., Heflich R.H. and Cerniglia, C.E., Reduction of nitroaromatic compounds by anaerobic bacteria isolated from the human intestinal tract. Appl Environ Mivrobiol, 57: 962-968, 1991.
4. Walker, R. and Ryan, A.J., Some molecular parameters influencing rate of reduction of azo compounds by intestinal microflora. Xenobiotica, 1: 483-486, 1971.
5. Azad Khan, A.K., Truelove, S.C. and Aronseq J.K., the disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol, 13: 523-528, 1982.
6. Chan, R.P., Pope, D.J., Gilbert, A.P.Baron, J.H. and Lennard-Jones, J.P., Studies of two novel sulfaslazine analogue: ipsalazine and balsalazine. Dig Dis Sci, 28: 609-615, 1983.
7. Hartalsky, A., Salicylazobenzoic acid in ulcerative colitis. Lancet, 1: 960, 1982.
8. Garreto, M., Ridell, R.H. and Wurans, C.S., Treatment of chronic ulcerative colitis with poly-ASA: A new nonabosrbable carrier for release of 5-aminosalicylic acid in the colon. Gastroenterology, 84: 1162, 1981.
9. Willoughby, C.P., Aronson, J.K., Agback, H., Bodin, N.O., Anderson, E. and Truelove, S.C., Disposition in normal volunteers of sodium azodisalicylate, a potential therapeutic agent in inflammatory bowl disease. Gut, 22: A431, 1981.
10. Willoughby, C.P., Aronson, J.K., Agback, H., Bodin, N.O., Anderson, E. and Truelove, S.C., Disposition in normal volunteers of sodium azodisalicylate, a potential therapeutic agent in ulcerative colitis. Gut, 23: 1081-1087, 1982.
11. Lauristein, K., Hansen, J., Ryde, H.M. and Rask-Madsen, J., Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology, 86: 1496-1500, 1984.
12. Sandberg-Gertzen, H., Ryde, H.M. and Janerot, G., Absorption, metabolism and excretion of a single 1 g dose of azodisal sodium in subjects with ileostom. Scan J Gastroenterol, 88: 107-111, 1983.
13. Van Hogezand, R.A., Van Hees, P.A.M., Zwaneburg, B., Van Rossum, J.M. and Van Tongeren, J.H.M. Disposition of sodium azodisalicylate in healthy subjects, Gastroenterolgy, 88: 717-722, 1985.
14. Rao, S.S.C., Read, N.W. and Holdsworth, C.D. Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Gut, 28: 1474-1477, 1987.
15. Pamucku, R., Hanauer, S. and Chang, E.B., Effect of disodium azosalicylate on electrolyte transport in the rabbit ileum and colon in vitro. Gastroenterology, 95: 975-981, 1988.
16. McIntyre, P.B., Rodrigues, C.A. and Lennard-Jones, J.E., Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther, 2: 237-243, 188.
17. Riley, S.A. and Turnberg, L.A., Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowl disease. Q J Med, 75: 561-562, 1990.
18. Klotz, U., Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokint, 10: 285-302, 1985.
19. Friendman, G., Sulphasalazine and new analogues. Am J Gastroenterol, 81: 141-144, 1986.
20. Garretto, M., Riddell, R.H. and Winans, C.S., Treatment of ulcerative colitis with poly-ASA: a new non-absorbable carrier for release of 5-aminosalicylic acid release in vitro. Gasroenterology, 16: 211-212, 1989.
21. Sakuma, S., Lu, Zheng-Rong, Kopeková, P. and Kopeek, J., Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Rel, 75: 365-379, 2001.
22. Friend, D.R., Glycosides in colonic drug delivery. In: Friend, D.R. (Ed). Oral colon specific drug delivery. CRC Press, Boca Raton, pp 153-187, 1992.
23. Pownall, J.H., Hickson, D.L. and Smith, L.C., Transport of Biological Lipophils: Effect of lipophilic structure. J Am Chem Soc, 105: 2440-2445, 1983.
24. Kobashi, K., Nishimura, T., Kusaka, M., Hottari, M. and Namba, T., Metabolism of sennoids by human intetinal bacteria. J Med Plant Res, 40: 225-236, 1980.
25. Conchie, J. and Macleod, D.C., Glycosidase in mammalian alimentary tract. Nature, 184: 1233, 1959.
26. Rubinstein, A., Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Carr Syst, 12: 101-149, 1995.
27. Friend, D.R. and Chang, G.W., A colon-specific drug delivery based on the drug glycosidases of colonic bacteria. J Med Chem, 27: 261-266, 1984.
28. Friend, D.R. and Chang, G.W., Drug Glycosides: Potential prodrug for colon-specific drug delivery. J Med Chem, 85: 51-57, 1985.
29. Friend, D.R. and Tozer, T.N., Drug glycoside in colon-specific drug delivery. J Control Rel, 19: 109-120, 192.
30. Friend, D.R., Philips, S, McLeod, A and Tozer, T.N., Relative anti-inflammatory effect of oral dexmamethasone-β-D-glucoside and dexamethasone in experimental inflammatory bowl disease in guinea pig. J Pharm Pharmacol, 43: 353-355, 1991.
31. Minami, K., Hiramaya, F. and Uekama, K., Colon-specific drug delivery based on cyclodextrin prodrug: release behaviour of biphenyl acetic acid form its cyclodextrin conjugates in rat intestinal tract after oral administration. J Pharm Sci, 87: 715-720, 1998.
32. Scheline, R.P., Drug metabolism by intestinal microorganism. J Pharm Sci, 57: 2021-2037, 1968.
33. Simpkins, J.W., Smulkowski, M., Dixon, R. and Tuttle, R., Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther, 244: 195-205, 1988.
34. Haeberlin, B., Rubas, W., Nolen, II, H.W. and Friend, D.R., In vitro evaluation of dexamethasone-β-D-glucuronide for colon-specific drug delivery. Pharm Res, 10: 1553-1562, 1993.
35. Mcleod, A.D., Feclorak, R.N., Friend, D.R., Tozer, T.N. and Cui, N., A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology, 106: 405-413, 1994.
36. Cui, N. Friend, D.R. and Fedorak, R.N., A Budesonide prodrug accelerates treatment of colitis in rats. Gut, 35: 1439-1446, 1994.
37. Fedorak, R.N., Haeberlin, B. and Empey, L.R., Colonic drug delivery of dexamethasone from a prodrug accelerates healing of colitis in rat without adrenal suppression. Gastroenterology, 108: 1688-1699, 1995.
38. Nolen, H.W. III, Fedorak, R.N. and Friend, D.R., Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rat. Biopharm Drug Dispos, 18: 681-695, 1997.
39. Loftsson, T., Brewster, M.E., Derendorf, H. and Bodor, N., 2-hydroxypropyl-β-cyclodextrin: properties and usage in pharmaceutical formulations. Pharm Ztg Wiss, 4: 5-10, 1991.
40. Uekama, K., Hiramaya, F. and Irie, T., Pharmaceutical uses of cyclodextrin derivatives. In: (Szycher, M., Ed.). High performance Biomaterials, Technomic publishing, Lancaster, pp 789-806, 1991.
41. Szejtli, J. and Szente, L. Ed. Proceedings of the Eighth international symposium on cyclodextrins, Kluwer, Dordrecht, 1996.
42. Stella, V.J. and Rajewski, R.A., Cyclodextrins: their future in drug formulation and delivery. Pharm Res, 14: 556-567, 1997.
43. Andersen, G.H., Robbins, F.M., Domingues, F.J., Morres, R.G. and Long, C.L., The utilisation of schardinger dextrins by the rat. Toxicol Appl Pharmacol, 5: 257-266, 1983.
44. Antenucci, R. and Palmer, J.K., Enzymatic degradation of α and β-cyclodextrins by bacteroids of the human colon. J Agric Food Chem, 32: 1316-1321, 1984.
45. Gerloczy, A., Fonagy, A. Keresztes, P., Perlaky, L. and Szejtli, J., Absorption, distribution, excretion and metabolism of orally administered 14C-β-cyclodextrin in rat. Arzneim Forsch / Drug Research, 35: 1042-1047, 1985.
46. Flourie, B., Molis, C. Achour, L., Dupas, H., Hatat, C. and Rambaud, J.C., Fate of β-cyclodextrin in the human intestine. J Nutr, 123: 676-680, 1993.
47. Karunaratne, D.N., Farmer, S. and Hancock, R.E.W., Synthesis of bulky beta-lactams for inhibition of cell surface beta-lactamase activity. Bioconjug Chem, 4: 434-439, 1993.
48. Tanaka, H., Kominato, K. and Yamamoto, R., Synthesis of doxorubicin-cyclodextrin connjugates. J Antibio, 47: 1025-1029, 1194.
49. Coates, J.H., Easton, C.J., Fryer, N.L. and Lincolin, S.F., Complementary diastereo selectivity in the synthesis and hydrolysis of acylated cyclodextrins. Chem Lett, 1153-1156, 1994.
50. Minami, K., Hiramaya, F. and Uekama, K., Colon-specific drug delivery based on a cyclodextrin prodrug: release behaviour of biphenyl acetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci, 87: 715-720, 1998.
51. Uekama, K., Minami, K. and Hirayama, F., 6A-O-[(4-biphenylyl)acetyl]-alpha-, -beta- and -gamma-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino]- alpha-, -beta-, and -gamma-cyclodextrins: potential prodrugs for colon-specific delivery. J Med Chem, 40:2755-61, 1997.
52. Hiramaya, F., Minami, K., and Uekama, K., In vitro evaluation of biphenyl acetic acid-beta-cyclodextrin conjugates as colon-targeting prodrugs: Drug release behaviour in rat biological media. J Pharm Pharmacol, 48: 27-31, 1996.
53. Yano, H., Hirayama, F., Kamada, M., Arima, H., Uekama, K. and Uekama, K., Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Rel, 79: 103-12, 2002.
54. Yano, H., Hiramaya, F., Arima, H. and Uekama, K., Preparation of prednisolone-appended α-, β- and γ-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behaviour. J Pharm Sci, 90: 493-503, 2001.
55. Frank, D.W., Gray, J.E. and Weaver, R.N., Cyclodextrin nephrosis in the rat. Am J Pathol, 83: 367-382, 1976.
56. Rajeskwi, R.A., Traiger, G., Bresnahan, A., Jaberaboansari, P., Stella, V.J. and Thompson, D.O., Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J Pharm Sci, 84: 927-932, 1995.
57. Gerloczy, A., Antal, S., Szatmari, I., Muller-Horvath, R. and Szejti, J., Mins 5th Int Symp cyclodextrins. Duchene, D. (Ed.) Editions de Sante: Paris, 507-513, 1990.
58. Monbaliu, J., Van Beijsterveldt, L., Meuldermans, W., Szathnari, S. and Heykants, J., Mins 5th Int Symp cyclodextrins. Duchene, D. (Ed.) Editions de Sante: Paris, 514-517, 1990.
59. Uekama, M., Horikawa, T., Yamanaka, M. and Hiramaya, F., Peracylated β-cyclodextrins as novel sustained release carries for a water soluble drug, molsidomine. J Pharm Pharmacol, 46: 714-717, 1994.
60. Larsen, C., Harboe, E., Johansen, M. and Olesen, H.P., Macromoleculer prodrugs. XVI. Colon targeted delivery. Comparison of the rate of release of naproxen from dextran ester prodrug in homogenates of various segments of the pig gastrointestinal tract. Pharm Res, 6: 995-999, 1989.
61. Harboe, E., Larsen, C., Johansen, M. and Olesen, H.P., Macromoleculer prodrugs. XV. Colon targeted delivery. Bioavailability of naproxen from orally administered dextran ester prodrugs varying molecular size in the pig. Pharm Res, 6: 919-923, 1989.
62. Harboe, E., Larsen, C., Johansen, M. and Olesen, H.P., Macromoleculer prodrugs. XIV. Absorption characteristics of naproxen after oral administration of a dextran T-70-naproxen ester prodrugs in pigs. Int J Pharm, 53: 157-165, 1989.
63. Johansen, M. and Larsen, C., Stability kinetics and of hydrolysis of metronidazole monosuccinate in aqueous solution and in plasma. Int J Pharm, 21: 201-209, 1984.
64. Johansen, M. and Larsen, C., A comparison of the chemical stability and the enzymatic hydrolysis of a series of aliphatic and aromatic ester derivatives of metronidazole. Int J Pharm, 27: 219-231, 1985.
65. Vermeersch, J., Vandoorne, F., Permentier, D. and Schacht, E., Macromoleculer prodrugs of metronidazole 1. Esterification of hydroxyl containing Polymers with metronidazole monosuccinate. Bull Soc Chim Belg, 94: 591-596, 1985.
66. McLeod, A.D., Friend, D.R. and Tozer, T.N., Synthesis and chemical stability of glucocorticoid-dextran ester: Potential prodrugs for colon-specific drug delivery. Int J Pharm, 92: 105-114, 1993.
67. McLeod, A.D., Tolentino, L. and Tozer, T.N., Glucocorticoid-dextran ester conjugates as Potential prodrugs for colon-specific drug delivery: Steady-state pharmacokinetics in rat. Biopharm Drug Dispos, 15: 151-164, 1994.
68. McLeod, A.D., Fedorak, R.N., Friend, D.R., Tozer, T.N. and Cui, N., A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology, 106; 405-413, 1994.
69. Nakamura, J., Asai, K., Nishida, K. and Sasaki, H.,A novel prodrug of salicylic acid, salicylic acid-glutamic acid conjugate utilising hydrolysis in rabbit intestinal microorganism. Chem Pharm Bull, 40: 2164-2168, 1992.
70. Nakamura, J., Kido, M., Nishida, K. and Sasaki, H., Hydrolysis of salicylic acid-tyrosine salicylic acid-methionine prodrugs in rabbits. Int J Pharm, 87: 59-66, 1992.
71. Nakamura, J., Kido, M., Nishida, K. and Sasaki, H., Effect of oral pretreatment with antibiotics on the hydrolysis of salicylic acid-tyrosine and salicylic acid-methionine prodrugs in rabbit intestinal microorganisms. Chem Pharm Bull, 40: 2572-2576, 1992.
72. Nakamura, J., Tagami, K., Nishida, K. and Sasaki, H., Unequal hydrolysis of salicylic acid-D-alanine and salicylic acid-L-alanine conjugate in rabbit intestinal microorganisms. Chem Pharm Bull, 40: 547-549, 1992.
73. Schacht, E., Gevaert, A. and Kenawy, E.R., Polymers for colon specific drug delivery. J Control Rel, 39: 327-328, 1996.
74. Schacht, E., Callant D. and Verstraete, W., Synthesis and evaluation of polymeric prodrugs of 5-aminosalicylic acid. Proc Int Symp Contr Rel Bioact Materl, 18: 686-687, 1991.
75. Leopold, C.S. and Friend, D.R., In vitro study for the assessment of poly(L-Aspartic acid) as a drug carrier for colon-specific drug delivery. Int J Pharm, 126: 139-145, 1995.
76. Leopold, C.S. and Friend, D.R., In vivo pharmacokinetics study for the assessment of poly(L-Aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm, 23: 397-406, 1995.
77. Wilding, I.R., Hardy, J.G., Sparrow, R.A., Davis, S.S, Daly, P.B. and English, J.R., In vivo evaluation of enteric coated naproxan tablets using gamma scintigraphy. Pharm Res, 9: 1436-1441, 1992.
78. Khan, M.Z.I., Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo date: challenges and opportunities. Int J Pharm, 140: 141-143, 1996.
79. Dressman, J.B., Amidon, C., Reppas, C. and Shah, V.P., Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms, Pharm Res, 15: 11-22, 1998.
80. Ashford, M., Fell, J.T., Attwood, D. and Woodhead, P.J., An in vitro investigation into the suitability of pH-dependent polymers for colon targeting. Int J Pharm, 91: 241-243, 1993.
81. Spitael, J. and Kinget, R., Solubility and dissolution rate of enteric polymers. Acta Pharm Technol, 25: 163-168, 1979.
82. Spitael, J. and Kinget, R., Factors affecting the dissolution rate of enteric coatings. Pharm Ind, 39: 502-505, 1977.
83. Spitael, J., Kinget, R. and Naessens, K., Dissolution rate of cellulose acetate phthalate and Bronsted catalysis. Pharm Ind, 42: 846-849, 1980.
84. Spitael, J. and Kinget, R., Influence of solvent composition upon film-coating. Pharm Acta Helv, 55: 157-160, 1980.
85. Touitou, E. and Rubinstein, A., Targeted eternal delivery of insulin to rats. Int J Pharm, 30: 95-99, 1986.
86. Thomos, P., Richards, D. and Richards, A., Absorption of delayed release prednisolone in ulcerative colitis and Chron's disease. J Pharm Pharmacol, 37: 757-758, 1985.
87. Van Saene, J.J.M., Van Saene, H.F.K., Geitz, J.N., Tarko-Smit, N.J.P. and Lerk, C.F., Quinolones and colonization resistance in human volunteers, Pharm Weekbl Sci Ed, 8: 67-71, 1986.
88. Azad Khan, K.A., Piris, J. and Truelove, S.C., An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet, 2: 892-895, 1977.
89. Bogentoft, C., Eskilsson, C., Jonsson, U.E., Lagerstorm, P.O., Lovgren, K. and Rosen, L., Delivery of drug to the colon by means of a new microencapsulated oral dosage form. Acta Phrarm Suec, 20: 311-314, 1983.
90. Watkinson, G., Sulphasalazine: A review of 40 years experience. Drugs, 32(suppl 1): 1-11, 1986.
91. Riley, S.A., Lecarpentier, J., Mani, V., Goodman, M.J., Mandal, B.K. and Turnberg, L.A., Sulphasalazine induced seminal abnormalities in ulcerative colitis: Results of mesalazine substitute. Gut, 28: 1008-1012, 1987.
92. Al Mardini, H., Lindsay, D.C., Deighton, C.M. and Record, C.A., Effect of polymer coating on faecal recovery of ingested 5-aminosalicylic acid in patients with ulcerative colitis. Gut, 28: 1084-1089, 1987.
93. Kim, C.K., Shin, H.J., Yang, S.G., Kim, J.H. and Oh, Y., Once a day oral dosing regimen of cycloscoporin A: Combined therapy of cycloscoporin a premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates, Pharm Res, 18: 454-459, 2001.
94. Levine, D.S., Raisys, V.A. and Ainardi, V., Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active anti inflammatory drug to the terminal ileum. Gastroenterology, 92: 1037-1044, 1987.
95. Hardy, J.G., Evans, D.F., Zaki, I., Clark, A.G., Tonnesen, H.H. and Gamst, O.N., Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring. Int J Pharm, 37: 245-250, 1987.
96. Khan, M.Z., Prebeg, Z. and Kurjakovic, N., A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J Control Rel, 58: 215-222, 1999.
97. Lorenzo-Lamosa, M.L., Remunan-Lopez, C., Vila-Jato, J.L. and Alonso, M.J., Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Rel, 52: 109-118, 1998.
98. Dew, M.J., Ryder, R.E.J., Evans, N., Evans, B.K. and Rhodes, J., Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmcol, 16: 185-187, 1983.
99. Dew, M.J., Ebden, P., Kidwai, S., Lee, G., Evans, B.K. and Rhodes, J., Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-aminosalicylic acid in normal subjects and in patients with colitis. Br J Clin Pharmcol, 17: 474-476, 1984.
100. Hardy, J.G., Healy, J..N.C. and Reynolds, J.R., Evaluation of an enteric coated delayed release 5-aminosalicylic acid tablet in patients with inflammatory bowl disease. Aliment Pharmacol Ther, 1: 273-280, 1987.
101. Schroeder, K.W., Tremaine, W.J. and Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitis. N Engl J Med, 317: 1625-1629, 1987.
102. Norlander, B., Gotthard, R. and Storm, M., Pharmacokinetics of 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther, 3: 333-342, 1989.
103. Jarnerot, G., Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs, 37: 73-86, 1989.
104. Faber, S.M. and Korelitz, B.I., Experience with Eudragit-S-Coated mesalamine (Asacol) in inflammatory bowl disease: An open study. J Clin Gastroenterol, 17: 213-218, 1993.
105. Morishita, I., Morishita, M., Takayama, K., Machida, Y. and Nagai, T., Enteral insulin delivery by microspheres in three different formulations using Eudragit L100 and S100. Int J Pharm, 91: 29-37, 1993.
106. Cole, E.T., Scott, R.A., Connor, A.L., Wilding, I.R., Petereit, H.U., Schminke, C., Beckert, T. and Cade, D., Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231: 83-95, 2002.
107. Peeters, R. and Kinget, R., Film-forming polymers for colonic drug delivery. I. Synthesis and physical and chemical properties of methyl derivatives of Eudragit S. Int J Pharm, 94: 125-134, 1993.
108. Rodríguez, M., Vila-Jato, J.L. and Torres, D., Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Rel, 55: 67-77, 1998.
109. Ashford, M., Fell, J.T., Attwood, D., Sharma, H. and Woodhead, P.J., An in vivo investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm, 95: 193-199, 1993.
110. Rodriguez, M., Antúnez, J.A., Taboada, C., Seijo, B. and Torres, D., Colon-specific delivery of Budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol, 53: 1207-15, 2001.
111. Markus, W. Rudolph, Klein, S., Beckert, T.E., Petereit, H. and Dressman, J.B., A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis Eur J Pharm Biopharm, 51: 183-190, 2001.
112. Saffran, M., Kumar, G.S., Savariar, C., Burnham, J.C., Williams, F. and Neckers, D.C., A new approach to the oral administration of insulin and other peptide drugs. Science, 233: 1081-1084, 1986.
113. Saffran, M., Bedra, C., Kumar, G.S. and Neckers, D.C., Vasopressin: a new model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci, 77: 33-38, 1988.
114. Saffran, M., Bedra, C., Kumar, G.S., Neckers, D.C., Pena, J., Jones, R.H. and Field, J.B., Biodegradable azo polymer coating for oral delivery of peptide drugs. Biochem Soc Trans, 18: 752-754, 1990.
115. Saffran, M., Field, J.B., Pena, J., Jones, R.H. and Okuda, Y., Oral insulin in diabetic dogs. J Endocrinol, 131: 267-278, 1991.
116. Van den Mooter, G., Samyn, C. and Kinget, R., Azo polymers for colon-specific drug delivery. Int J Pharm, 87: 37-46, 1992.
117. Van den Mooter, G., Samyn, C. and Kinget, R., Azo polymers for colon-specific drug delivery. Part II: Influence of the type of azo polymer on the degradation by intestinal microflora. Int J Pharm, 97: 133-139, 1993.
118. Kinget, R., Kalala, W., Vervoort, L. and Van den Mooter, G., Colonic drug targeting. J Drug Target, 6:129-149, 1998.
119. Van den Mooter, G., Samyn, C. and Kinget, R., Characterisation of colon-specific azo polymers: A study of the swelling properties and the permeability of isolated polymer films. Int J Pharm, 11: 127-136, 1994.
120. Van den Mooter, G., Samyn, C. and Kinget, R., In vivo evaluation of a colon-specific drug delivery system: An absorption study of theophylline from capsules coated with azo polymers in rat. Pharm Res, 12: 244-247, 1995.
121. Kalala, W., Kinget, R., Van den Mooter, G. and Samyn, C., Colonic drug-targeting: in vitro release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. Int J Pharm, 139: 187-195, 1996.
122. Symn, C., Kala, W., Van den Mooter, G. and Kinget, R., Synthesis and in vitro biodegradation of poly(ether-ester) azo polymers designed for colon targeting. Int J Pharm, 121: 211-216, 1995.
123. Kimura, Y., Makita, Y., Kumagi, T., Yamane, T., Kiato, H., Sasatani, H. and Kim, S.I., Degradation of azo-containg polyurethane by the action of intestinal flora: its metabolism and application as a drug delivery system. Polymer, 33: 5294-5299, 1992.
124. Ueda, T., Yamaoka, M., Miyamoto, M. and Kimura, Y., Bacterial reduction of azo compounds as a model reaction for the degradation of azo-containing polyurethane by the action of intestinal flora. Bull Chem Soc Jpn, 69: 1139-1142, 1996.
125. Yamaoka, T., Makita, Y., Sasatani, H., Kim, S.I. and Kimura, Y., Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behaviour, and utilization for drug formulation. J Control Rel, 66: 187-97, 2000.
126. Chavan, M.S., Sant, V.P. and Nagarsenker, M.S., Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in-vitro evaluation. J Pharm Pharmacol, 53: 895-900, 2001.
127. Lehmann, K.O.R. and Drehher, Methacrylated galactomannan coating for colon-specific drug delivery. Proc Int Symp Contrl Rel Bioact Mater, 18: 331-332, 1991.
128. Vervoort, L. and Kinget, R., In vitro degradation by colonic bacteria of inulin HP incorporated in Eudragit RS films. Int J Pharm, 129: 185-190, 1996.
129. Wakerly, Z., Fell, J.T., Attwood, D. and Parkins, D., Pectin/ ethyl cellulose film coating formulation for colonic drug delivery. Pharm Res, 13: 1210-1212, 1996.
130. Brondsted, H., Andersen, C. and Hovgaard, L., Crosslinked dextran - a new capsule material for colon targeting of drugs. J Control Rel, 53: 7-13, 1998.
131. Bauer, K.H. and Kesselhut, J.F., Novel pharmaceutical excipients for colon targeting. STP Pharm Sci, 5: 54-59, 1995.
132. Hirsch, S., Binder, V., Kolter, K., Kesselhut, J.F., and Bauer, K.H., Lauroyldextrin as a coating material for site-specific drug delivery to the colon: In vitro dissolution of coated tablets. Proc Int Symp Contrl Rel Bioact Mater, 24: 379-380, 1997.
133. Lamprecht, A., Torres, H.R., Schafer, U. and Lehr, C.M., Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease, J Control Rel, 69: 445-454, 2000.
134. Rubinstein, A., Radai, R., Ezra, M., Pathak, S. and Rokem, J.M., In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. Pharm Res, 10: 258-263, 1993.
135. Rubinstein, A. and Radai, R., Pectic salt as a colonic delivery system. Proc Int Symp Contrl Rel Bioact Mater, 18: 221-222, 1991.
136. Ashford, M., Fell, J.T., Attwood, D., Sharma, H. and Woodhead, P., Studies on pectin formulations for colonic drug delivery. J Control Rel, 30: 225-232, 1994.
137. Wakerly, Z., Fell, J.T., Attwood, D. and Parkins, D., Studies on drug release from pectin/ ethylcellulose film-coated tablets: a potential colonic delivery system. Int J Pharm, 153: 219-224, 1997.
138. Macleod, G.S., Fell, J.T. and Collett, J.H., Studies on the physical properties of mixed pectin/ ethylcellulose films intended for colonic drug delivery. Int J Pharm, 157: 53-60, 1997.
139. Fernandez-Hervas, M.J. and Fell, J.T., Pectin/ chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int J Pharm, 169: 115-119, 1998.
140. Macleod, G.S., Fell, J.T., Collett, J.H., Sharma, J.L. and Smith, A.M., Selective drug delivery to the colon using pectin: chitosan: hydyroxypropyl methylcellulose film coated tablets. Int J Pharm, 187: 251-257, 1999.
141. Turkoglu, M., Ugurlu, T., In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur J Pharm Biopharm, 53: 65-73, 2002.
142. Semde, R., Amighi, K., Devleeschouwer, M.J. and Moes, A.J., Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. Int J Pharm, 197:169-179, 2000.
143. Semde, R., Amighi, K., Devleeschouwer, M.J. and Moes, A.J., Studies of pectin HM/Eudragit RL/Eudragit NE film-coating formulations intended for colonic drug delivery. Int J Pharm, 197: 181-92, 2000.
144. Munjeri, O., Collett, J.H. and Fell, J.T., Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. J Control Rel, 46: 273-278, 1997.
145. Sriamornsak, P. and Nunthanid, J., Calcium pectinate gel beads for controlled release drug delivery: I. Preparation and in vitro release studies. Int J Pharm, 160: 207-212, 1998.
146. El-Gibaly, I., Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm, 232: 199-211, 2002.
147. Grahan, N.B., McNeil, M.E., Hydrogels for controlled drug delivery, Biomaterials, 5: 27-36, 1984.
148. Bae, Y.H. and Kim, S.W., Hydrogels delivery systems based on polymer blends, block-copolymers or interpenetrating networks, Adv Drug Del Rev, 11: 109-135, 1993.
149. Kopecek, J., Kopeckova, P. and Brondsted, H., Polymers for colon-specific oral drug delivery. J Control Rel, 19: 121-130, 1992.
150. Shanta, K.L., Ravichandran, P. and Rao, K.P., Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials, 16: 1313-1318, 1995.
151. Brondsted, H., Kopeckova, P., Hydrogels for site-specific oral drug delivery: Synthesis and characterisation. Biomaterials, 12: 584-592, 1991.
152. Brondsted, H. and Kopecek, J., Hydrogels for site specific drug delivery to colon: in vitro and in vivo degradation, Pharm Res, 9: 1540-1545, 1992.
153. Ghandehari, H., Kopecekova, P. and Kopecek, J., In vitro degradation of pH-sensitive hydrogels containing aromatic azo bonds. Biomaterials, 18: 861-72, 1997.
154. Ulbrich, K., Strohalm, J. and Kopecek, J., Polymers containing enzymatically degradable bonds. VI. Hydrophilic gels cleavable by chymotrypsin. Biomaterials, 3: 150-154, 1982.
155. Vervoort, L., Rombaut, P., Van den Mooter, G., Augustijns, P. and Kinget, R., Inulin hydrogels. II. In vitro degradation study. Int J Pharm, 172: 137-145, 1998.
156. Vervoort, L., Rombaut, P., Van den Mooter, G., Augustijns, P. and Kinget, R., Inulin hydrogels. I. Dynamic and equilibrium swelling properties. Int J Pharm, 172: 127-135, 1998.
157. Maris, B., Verheyden,L., Reeth, K.V., Samyn, C., Augustijns, P., Kinget, R. and Van den Mooter, G., Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int J Pharm, 213: 143 - 152, 2001.
158. Vervoort, L., Van den Mooter, G., Augustijns, P., Busson, R., Toppet, S. and Kinget, R., Inulin hydrogels as carrier for colonic drug targeting :I. Synthesis and characterization of methacrylated inulin and hydrogel formation. Pharm Res, 14: 1730-1736, 1997.
159. Stubbe, B., Maris, B., Van den Mooter, G., and Demeester, J., The in vitro evaluation of azo containing polysaccharide gels' for colon delivery. J Control Rel, 75: 103-114, 2001.
160. Hovgaard, L. and Brondsted, H., Dextran hydrogels for colon-specific drug delivery. J Control Rel, 36: 159-166, 1995.
161. Chiu, H.C., Hsiue, G.H., Lee, Y.P. and Huang, L.W., Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. J Biomater Sci Polym Ed, 10: 591-608, 1999.
162. Orienti, T., and Zecchi, V., Hydrogels formed by cross-linked polyvinylalcohol as colon-specific drug delivery systems. Drug Dev Ind Pharm, 27: 877-84, 2001.
163. Sintov, A., Ankol, S., Levy, D. and Rubinstein, A., Enzymatic cleavage of disaccharide side groups in insoluble synthetic polymers: a new method for specific delivery of drugs to the colon. Biomaterials, 14: 483-490, 1993.
164. French, D.L. and Mauger, J.W., Evaluation of the physiochemical properties and dissolution characteristics of mesalamine: Relevance to controlled intestinal drug delivery. Pharm Res, 10: 1285-1290, 1993.
165. Cen, M., Uzun, C. and Güven, O., Controlled release of terbinafine hydrochloride from pH sensitive poly(acrylamide/ maleic acid) hydrogels Int J Pharm, 203: 149-157, 2000.
166. Goldsten, A..M., Alter, E..N. and Seaman, J.K., Guar gum, In: Whistler R.L. (Ed.). Oral colon specific drug delivery and their derivatives, Academic press, Florida, pp. 1-43, 1992.
167. Johnson, J.C. and Gee, J..M., Effect of gel forming gum on the intestinal unstirred layer and sugar transport in vitro. Gut, 22: 398-403, 1981.
168. Tomlin, B.J., Read, N.W., Edwards, C..A. and Duerden, B.I., The degradation of guar gum by fecal incubation system. Brit J Nutrn, 55: 481-86, 1986.
169. Gliko-Kabir, I., Yagen, B., Penhasi, A. and Rubinstein, A., Phosphated crosslinked guar for colon-specific drug delivery. I. Preparation and physicochemical characterization. J Control Rel, 63: 121-127, 2000.
170. Gliko-Kabir, I., Yagen, B., Baluom, M. and Rubinstein, A., Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation, J Control Rel, 63: 129-134, 2000.
171. Rama Prasad, Y.V., Krishnaiah, Y.S.R. and Satyanarayana, S., In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J Control Rel, 51: 281-287, 1998.
172. Gliko-Kabir, I., Yagen, B., Penhasi, A. and Rubinstein, A., Low swelling, crosslinked guar and its potential use as colon-specific drug carrier. Pharm Res, 15: 1019-1025, 1998.
173. Krishnaiah Y.S.R., Seetha Devi, A, Nageswara Rao, L, Bhaskar Reddy, P.R., Karthikeyan. R.S., Satyanarayana, V., Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. J Pharm Pharmaceut Sci, 4: 235-243, 2001.
174. Krishnaiah, Y.S.R., Veer Raju, P., Dinesh Kumar, B., Bhaskar, P. and Satyanarayana, V., Development of colon targeted drug delivery systems for mebendazole. J Control Rel, 77: 87-95, 2001.
175. Krishnaiah, Y.S.R., Satyanarayana, S., Rama Prasad, Y.V. and Narasimha Rao, S., Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy subjects. J Control Rel, 55: 245-252, 1998.
176. Milojevic, S., Newton, J.M., Cummings, J.H., Gibson, G.R., Botham, R.L., Ring, S.C., Stockham, M. and Allwood, M.C., Amylose as a coating for drug delivery the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Rel, 38: 75-84, 1996.
177. Milojevic, S., Newton, J.M., Cummings, J.H., Gibson, G.R., Botham, R.L., Ring, S.C., Stockham, M. and Allwood, M.C., Amylose as a coating for drug delivery the colon: Preparation and in vitro evaluation using glucose pellets. J Control Rel, 38: 85-94, 1996.
178. Lenaerts V., Dumoulin Y. and Mateescu M. A., Controlled release of theophylline from crosslinked amylose tablets. J Control Rel, 15: 39-46, 1991.
179. 13C]glucose microspheres as a model for drug delivery to the colon. J Control Rel, 40: 123-131, 1996.
180. Salyers, A.A., Energy sources of major ntestinal fermentative anaerobes. Am J Clin Nutr, 32: 158-163, 1979.
181. Rubinstein, A., Nakar, D. and Sintov, A., Chondroitin sulphate: A potential biodegradable carrier for colon-specific drug delivery. Int J Pharm, 84: 141-150, 1992.
182. Rubinstein, A., Nakar, D. and Sintov, A., Colonic drug delivery: Enhanced release of indomethacin from cross linked chondroitin matrix in rat caecal content. Pharm Res, 9: 276-278, 1992.
183. Sintov, A., Di-Capua, N. and Rubinstein, A., Cross-linked chondroitin sulphate: characterization for drug delivery purposes. Biomaterials, 16: 473-8, 1995.
184. Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., Yamamoto, A. and Muranishi, S., Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci, 86: 1016-21, 1997.
185. Tozaki, H., Odoriba, T., Okada, N., Fujita, T., Terabe, A., Suzuki, T., Okabe, S., Murnishi, S. and Yamamoto, A., Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Rel, 82, 51-61, 2002.
186. Aiedeh, K., and Taha, M.O., Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered colon-specific drug delivery systems. Arch Pharm (Weinheim), 332: 103-7, 1999.
187. Tozaki, M., Fujita, T. and Odoriba, T., Colon specific delivery of R68070, a new thromboxane synthetase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. Life Sci, 64: 1155-1162, 1999.
188. Tozaki, M., Emi, Y., Horisaka, E., Fujita, T., Yamamoto, A. and Muranishi, S., Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: Implications in peptide delivery to the colon. J Pharm Pharmacol, 49: 164-168, 1997.
189. Vandelli, M.A., Leo, E., Forni, F. and Bernatei, M.T., In vitro evaluation of a potential colonic drug delivery system that releases drug after a controllable lag-time. Eur J Pharm Biopharm, 43: 148-151, 1996.
190. Shu, X.Z., Zhu, K.J. and Song, W., Novel pH-sensitive citrate crosslinked chitosan film for drug controlled release. Int J Pharm, 212: 19-28, 2001.
191. Zhang, H., Ibrahim, A.A., and Neau, S.H., An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int J Pharm, 239: 197-205, 2002.
192. Shimono, N., Takatori, T., Masumi, T., Ueda, M., Mori, M., Higashi, Y. and Nakamura, Y., Chitosan dispersed system for colon-specific drug delivery. Int J Pharm, 245: 45-54, 2002.
193. Orienti, I., Cerchiara, T., Luppi, B., Bigucci, F., Zuccari, G. and Zecchi, V., Influence of different chitosan salt on the release of sodium diclofenac in colon-specific delivery. Int J Pharm, 238: 51-59, 2002.
194. Krogars, K., Heinamaki, J., Vesalahti, J., Marvola, M., Antikainen, O., Yliruusi, J., Marvola, M. and Yliruusi, J., Extrusion-spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int J Pharm, 199: 187-94, 2000.
195. Nykanen, P., Krogars, K., Sakkinen, M., Heinamaki, J., Jurjensson, H., Veski, P. and Marvola, M., Organic acids as excipients in matrix granules for colon-specific drug delivery. Int J Pharm, 184: 251-61, 1999.
196. MacNeil, M.E., Rashid, A. and Stevens, H.N.E., Dispensing device. World Patent. WO 9009168, 1990.
197. Wilding, I.R., Hardy, J.G., Sparrow, R.A., Daviss, S.S., Daly, P.B. and English, J.R., In vitro evaluation of enteric-coated naproxan tablets using γ-scintigraphy. Pharm Res, 9: 1436-1441, 1992.
198. Binns, J.S., Stevens, H.N.E., Bakhashaer, M. and Wilson, G.G., Colon targeted release using the Pulsincap delviery system. Int Symp Controlled Rel Bioact Mater, 21: 260-261, 1994.
199. Gazzaniga, A., Bussetti, C., Moro, L., Sangali, M.E. and Giordano, F., Time dependent oral delivery system for colon targeting. STP Pharm Sci, 5: 83-88, 1995.
200. Gazzaniga, A., Iamartino, P., Maffione, G. and Sangalli, M.E., Oral delayed release system for colon specific drug delivery. Int J Pharm, 108: 77-83, 1994.
201. Gupta, V. K., Beckert, T.E. and Price, J.C., A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm, 213: 1-2:83 - 91, 2001.
202. Ishibashi, T., Hatano, H., Kobayashi, M., Mizobe, M. and Yoshino, H., Design and evaluation of a new capsule-type dosage form for colon-targeted delivery of drugs. Int J Pharm, 168: 31-40, 1998.
203. Fukui, E, Miyamura, N., Uemura, K. and Kobayashi, M., Preparation of enteric coated timed release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm, 204: 7 - 15, 2000.
204. Fukui, E., Miyamura, N. and Kobayashi, M., An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting. J Control Rel, 70: 97-107, 2001.
205. Gupta, V.K., Assmus, M.W., Beckert, T.E. and Price, J.C., A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. Int J Pharm, 213: 93-102, 2001.
206. Pozzi, F., Furlani, P., Gazzaiga, A., Daviss, S.S. and Wilding, I.R., A new oral dosage form for fast and complex release of drug after a predetermined lag time. J Control Rel, 31: 99-104, 1994.
207. Niwa, K., Takaya, T., Morimoto, T. and Takada, I., Preparation and evaluation of a time-controlled release capsule made of ethyl cellulose for colon delivery of drugs. J Drug Target, 3: 83-89, 1995.
208. Muraoka, M., Kimura, G., Zhaopeng, H. and Takada, K., Ulcerative colitis - colon delivery of 5-aminosalicylic acid. Nippon Rinsho, 56: 788-794, 1998.
209. Takaya, T., Niwa, K., Muraoka, M., Ogita, I., Nagai, N., Yano, R., Kimura, G., Yoshikawa, Y., Yoshikawa, H. and Takada, K., Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Rel, 50: 111-122, 1998.
210. Muraoka, M., Hu, Z., Shimokawa, T., Sekino, S., Kurogoshi, R., Kuboi, Y., Yoshikawa Y. and Takada, K., Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Rel, 52: 119-129, 1998.
211. Shibata, N., Ohno, T., Shimokawa, T., Hu, Z., Yoshikawa, Y., Koga, K., Murakami, M. and Takada, K., Application of pressure-controlled colon delivery capsules to oral administration of glycyrrizin in dogs. J Pharm Pharmacol, 53: 441-447, 2001.
212. Sangalli, M.E., Maroni, A., Zema, L., Busetti, C., Giordano, F. and Gazzaniga, A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Rel, 73: 103-110, 2001.
213. Gingell, R. and Walker, R, Mechanism of azo reduction by non-specificity of Streptococcus faecalis azo reductase. Xenobiotica, 5: 563-571, 1975.
214. Roxon, J.J., Ryan, A.J. and wright, S.E., Enzymatic reduction of tartrazine by Proteus vulgaris from rats. Food Cosmet Toxicol, 5: 645-656, 1967.
215. Bragger, J.L., Lloyd, A.W., Soozandehfar, S.H., Bloomfield, S.F., Marriott, C. and Martin, G.P., Investigations into the azo reducing activity of a common colonic microorganism. Int J Pharm, 157: 61-71, 1997.
216. Larsel, G.L., Larson, J.P. and Gustafsson, J.A., Cystein conjugate beta-lyase in the gastrointestinal bacterium Fusobacterium necrophorum. Xenobiotica, 13: 687-693, 1983.
217. Schacht, E. and Wilding, I.R., Process for the preparation of azo- and/or disulfide-containing polymers. WO 9111175.
218. Kimura, Y., Kim, S. and Nishiura, A., Polyurethanes. European Patent. EP 0398472, 1991.
219. Kimura, Y., Makita, Y., and Kumagai, T., Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and application as a drug delivery. Polymer, 33: 5294-5299, 1992.
220. Gurny, R., Junginger, H.E., Bioadhesion-possibilities and future trends. Wissenchaftliche Verlag, Stuttgart, 1989.
221. Lenaerts, V. and Gurny, R., Bioadhesive drug delivery systems. CRC Press, Boca Raton, 1990.
222. Chickering, D.E. and Mathiowitz, E., Bioadhesive microspheres. 1. A novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal mucosa. J Control Rel, 34: 251-262, 1995.
223. Chickering, D.E., Jacob, J.S. and Mathiowitz, E., Bioadhesive microspheres. 2. Characterisation and evaluation of bioadhesion involving hard, bioerodible polymers and soft-tissue. Reacting Polymers, 25: 189-206, 1995.
224. Khosla, R. and Davis, S.S., The effect of polycarbophil on the gastric emptying of pellets. J Pharm Pharmacol, 39: 47-49, 1987.
225. Haris, D., Fell, J.T., Sharma, H.L. and Taylor, D.C., GI transit of potential bioadhesive formulations in men: A scintigraphy study. J Control Rel, 12: 45-53, 1990.
226. Kakoulides, E.P., Smart, J.D. and Tsibouklis, J., Azocross-linked poly(acrylic acid) for colonic delivery and adhesion specificity: synthesis and characterisation. J Control Rel, 52: 291-300, 1998.
227. Kakoulides, E.P., Smart, J.D. and Tsibouklis, J., Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J Control Rel, 54: 95-109, 1998.
228. Pellicciari, R. Garzon-Aburbeh and Natalini, B., Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid. J Med Chem, 36: 4201-4207, 1993.
229. Rihova, B., Bioadhesive polymers for oral drug delivery. Adv Exp Med Biol, 371B: 1491-1494, 1995.
230. Brown J.P., McGarrough, G.V., Parkinson, T.M., Wingerd, R.E. Jr. and Onderdonk, A.B., Polymeric drug for treatment of inflammatory bowl disease. J Med Chem, 26: 1300-1307, 1983.
231. Kopecek, J., The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J Control Rel, 11: 279-290, 1990.
232. Kopecekova, P., Rathi, R., Takada, S., Rihova, B., Berenson, M.M. and Kopecek, J., Bioadhesive N-(2-hydroxypropyl) methacrylamide copolymers for colon-specific drug delivery. J Control Rel, 28: 211-222, 1994.
233. Jalan, K.N. and Maitra, T.K. Amebiasis in the developing world. In: Ravidin, J.I.(Ed.)., Amebiasis: human infections by Entamoeba histolytica. John Wiley and Sons, New York, pp 535-55, 1988.
234. Mirelman, D., De Meester, F., Stolarsky, T., Burchard, G.D., Ernst-Cabrera, K. and Wilcheck, M., Effects of covalently bound silica-nitroimidazole drug particles on Entamoeba histolytica. J Inf Dis, 159: 303-309, 1989.
235. Theeuwes, F., Guittard, G. and Wong, P., Delivery of drugs to colon by oral dosage forms. US Patent 4904474, 1990.
236. Swanson, D., Barclay, B., Wong, P. and Theeuwes, F., Nifedipine gastro-intestinal therapeutics system. Am J Med, 83 (suppl. 6B): 3, 1987.